The Drug Enforcement Administration’s Toxicology Testing Program (DEA TOX) began in May 2019 as a surveillance program aimed at...
Reports
The objective of this report is to provide guidance in developing an appropriate analytical scope of testing for NPS...
NPS Alert: Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replace Eutylone in Drug Supply Typically Sold as “Ecstacy” or “Molly”
/ /
The objective of this announcement is to notify public health and safety, law enforcement, first responder, clinicians, medical examiners...
This report provides up-to-date information regarding the status of NPS opioid prevalence and positivity within the United States
This report provides up-to-date information regarding NPS stimulant & NPS hallucinogen prevalence and positivity within the United States.
This report provides up-to-date information regarding the status of NPS benzodiazepine prevalence and positivity within the US.
This report provides up-to-date information regarding the status of synthetic cannabinoid prevalence and positivity within the United States.
Ohio Governor Mike DeWine today signed Executive Order 2022-05D to suspend the normal rulemaking process to allow the State...
Kit Check's Hospital Pharmacy Operations Report survey is a road map forward—shedding light on the state of the industry...
The World Health Organization published the meeting report of the 44th Expert Committee on Drug Dependence (ECDD)
Trending Reports
-
DEA Toxicology Testing Program – 2022 Q1 Report May 20, 2022
-
Recommended Scope for NPS Testing in the United States: Q1 2022 May 12, 2022
-
NPS Alert: Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replace Eutylone in Drug Supply Typically Sold as “Ecstacy” or “Molly” April 22, 2022
-
Trend Report: NPS Opioids in the US – Q1 2022 April 12, 2022
-
Trend Report: NPS Stimulants & Hallucinogens in the US – Q1 2022 April 12, 2022